Table 1.

Subject characteristics and baseline measurements

	Randomization Order
	Atorvastatin First	Slo-Niacin First
Number of Subjects	19	17
Men/Women	13/6	10/7
Post-menopausal	5	4
Caucasian/African-American	19/0	16/1
Smokers (No/Yes)	19/0	14/3
Hypertensive (No/Yes)	16/3	12/5
Mean±SD:
Age (years)	57.1±10.3	52.2±9.4
BMI (kg/m2)	32.8±6.5	32.3±5.5
Waist circumference (cm)	105.5±10.4	108.8±11.7
Lipoprotein lipids (mg/dL)
Triglyceride	188±75 (177)	185±93 (160)
Cholesterol (C)	249±40	241±56
LDL-C	177±28	164±26
Non HDL-C	210±39	202±52
Apo B	116±26	104±28
RLP-C	21.5±12.4 (16.5)	27.6±36.4 (13.3)
HDL-C	38±4	39±6
HDL2-C	5.6±2.5	6.4±2.7
Apo A-I	129±12	128±14
Glucose (mg/dL)	100±11	98±7
Insulin (µU/ml)	24±14	27±13
Median:
hsCRP (mg/dL)	2.7	1.6
TNFα (pg/mL)	14.5	15.6
IL-6 (pg/mL)	18.9	31.2